/KNTE

KNTE Stock - Kinnate Biopharma Inc.

Q: What is the analyst price target for KNTE?

Analyst price target information is not currently available for KNTE.

Q: What is KNTE's market cap?

Market capitalization information is not currently available for KNTE.

Healthcare|Biotechnology|NASDAQ

$2.65-0.38%

$0.01 (-0.38%) • Apr 2

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+1032.1%upside

Target: $30.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for KNTE

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.34

52W High$7.18

52W Low$1.04

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-799,000	$-604,000	$-123,000	$-83,000	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-119,008,000	$-118,521,000	$-90,111,000	$-36,001,000	$-12,012,000
Net Income	$-112,649,000	$-114,021,000	$-89,415,000	$-35,433,000	$-11,926,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-2.42	$-2.59	$-2.05	$-0.81	$-0.28

Company Overview

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

$22

Average Target

↑ 730.2% Upside

Now

$11

Low

$22

Average

$33

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 17th 2022	Stifel	Downgrade	Hold	$11← $35
July 28th 2022	H.C. Wainwright	Initiation	Buy	$33

Earnings History & Surprises

KNTE

Beat Rate

43%

Last 14 quarters

Avg Surprise

-7.6%

EPS vs Estimate

Beats / Misses

6/6

2 met exactly

Latest EPS

$-0.73

Q2 2024

EPS Surprise History

Q3 22

+4.6%

$-0.62vs$-0.65

Q4 22

-16.7%

$-0.70vs$-0.60

Q1 23

-2.9%

$-0.72vs$-0.70

Q2 23

0.0%

$-0.73vs$-0.73

Q3 23

+10.5%

$-0.68vs$-0.76

Q4 23

+5.8%

$-0.65vs$-0.69

Q1 24

+14.3%

$-0.36vs$-0.42

Q2 24

-114.7%

$-0.73vs$-0.34

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 9, 2024	$-0.34	$-0.73	-114.7%	✗ MISS
Q1 2024	Mar 27, 2024	$-0.42	$-0.36	+14.3%	✓ BEAT
Q4 2023	Nov 9, 2023	$-0.69	$-0.65	+5.8%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.76	$-0.68	+10.5%	✓ BEAT
Q2 2023	May 11, 2023	$-0.73	$-0.73	0.0%	= MET
Q1 2023	Mar 15, 2023	$-0.70	$-0.72	-2.9%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.60	$-0.70	-16.7%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.65	$-0.62	+4.6%	✓ BEAT
Q2 2022	May 12, 2022	$-0.62	$-0.61	+1.6%	✓ BEAT
Q1 2022	Mar 28, 2022	$-0.60	$-0.60	0.0%	= MET
Q4 2021	Nov 10, 2021	$-0.55	$-0.57	-3.6%	✗ MISS
Q3 2021	Aug 16, 2021	$-0.44	$-0.49	-11.4%	✗ MISS
Q2 2021	May 17, 2021	$-0.37	$-0.40	-8.1%	✗ MISS
Q1 2021	Mar 29, 2021	$-0.37	$-0.32	+13.5%	✓ BEAT
Q4 2020	Dec 2, 2020	—	$-0.33	—	—
Q3 2020	Sep 30, 2020	—	$-0.26	—	—
Q1 2020	Mar 31, 2020	—	$-0.17	—	—
Q4 2019	Dec 31, 2019	—	$-0.09	—	—

Frequently Asked Questions about KNTE

What is KNTE's current stock price?

Kinnate Biopharma Inc. (KNTE) is currently trading at $2.65 per share. The stock has moved -0.38% today.

What is the analyst price target for KNTE?

The average analyst price target for KNTE is $30.00, based on 1 analyst.

What sector is Kinnate Biopharma Inc. in?

Kinnate Biopharma Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is KNTE's market cap?

Kinnate Biopharma Inc. has a market capitalization of $0.12 billion, making it a small-cap company.

Does KNTE pay dividends?

No, Kinnate Biopharma Inc. does not currently pay a dividend to shareholders.